基于网络药理学和细胞功能实验探究石榴治疗胃癌的分子药理作用机制OA
Molecular pharmacological mechanism of pomegranate in the treatment of gastric cancer based on network pharmacology and cell functional assays
目的 基于网络药理学和细胞功能实验探究石榴治疗胃癌的作用机制.方法 利用 TCMSP、Herb2.0数据库获取石榴活性成分及靶点;通过 OMIM、TTD、GeneCards数据库获取胃癌相关靶点,将"石榴"与"胃癌"靶点取交集获得共同靶点.利用 STRING 和 Cytoscape 构建 PPI网络,CytoNCA筛选关键靶点;利用 DAVID 数据库进行基因本体论(GO)和京都基因与基因组百科全书(KEGG)富集分析,基迪奥平台可视化;AutoDock与 PyMOL进行分子对接.细胞实验采用细胞计数试剂盒-8(CCK-8)检测活力,平板克隆检测增殖,明场拍照观察细胞形态,Western blot 检测蛋白表达.结果 共获得石榴活性成分 8个,潜在靶点 225个,胃癌相关靶点 1 795个,交集 122个.GO 富集 289个条目,涉及激素应答、凋亡调控等;KEGG 富集 133条通路,包括磷脂酰肌醇 3-激酶/蛋白激酶B(PI3K/AKT)、丝裂原活化蛋白激酶/细胞外信号调节激酶(MAPK/ERK)等.PPI网络含 122节点、1 018条边,筛选出白细胞介素-6(IL-6)、表皮生长因子受体(EGFR)、肿瘤蛋白 p53(TP53)、蛋白激酶 B1(AKT1)4个关键靶点.CCK-8显示石榴剂量依赖抑制人胃癌细胞 HGC-27和 AGS 活力(例如 50 mg/mL处理 24 h后,细胞活力分别为对照组的 11%和 46%,均 P<0.001).平板克隆表明 HGC-27和 AGS细胞增殖能力下降.Western blot 显示 B细胞淋巴瘤-2(Bcl-2)、磷酸化蛋白激酶 B(p-AKT)、磷酸化细胞外信号调节激酶(p-ERK)表达下调,Bcl-2相关 X蛋白(Bax)、聚腺苷二磷酸核糖聚合酶(PARP)上调,均 P<0.05,总蛋白激酶 B(pan-AKT)、总细胞外信号调节激酶(pan-ERK)表达无明显变化,均 P>0.05.结论 石榴可通过调控 PI3K/AKT、MAPK/ERK 等信号通路抑制胃癌细胞的生长增殖活性,从而起到治疗胃癌的作用.
Objective To investigate the mechanism underlying the therapeutic effects against gastric cancer based on network pharmacology and cell function assays.Methods The active components of pomegranate and their putative targets were collected from the TCMSP and Herb2.0 databases.Gastric cancer-related targets were obtained from OMIM,TTD,and GeneCards databases,and the intersection between pomegranate-related targets and gastric cancer-related targets was used to identify shared targets.A PPI network was constructed using STRING and Cytoscape,and key targets were screened with CytoNCA.GO and KEGG enrichment analyses were performed using the DAVID database and visualized on the OmicShare platform.Molecular docking was conducted with AutoDock and visualized using PyMOL.For cellular experiments,cell viability was assessed by CCK-8,proliferation by colony formation assay,cell morphology by bright-field imaging,and protein expression by Western blotting.Results Eight active components of pomegranate were identified,along with 225 potential targets.A total of 1,795 gastric cancer-related targets were collected,yielding 122 intersecting targets.GO enrichment yielded 289 terms,involving hormone response and regulation of apoptosis,among others.KEGG enrichment identified 133 pathways,including PI3K/AKT and MAPK/ERK signaling.The PPI network comprised 122 nodes and 1,018 edges,and four key targets were screened:IL-6,EGFR,TP53,and AKT1.CCK-8 assays showed that pomegranate inhibited the viability of HGC-27 and AGS cells in a dose-dependent manner(for instance,after 24-hour treatment with 50 mg/mL,the cell viability was 11%and 46%of the control group,respectively,both P<0.001).Colony formation assays indicated HGC-27 and AGS cells reduced proliferative ability.Western blotting showed downregulation of Bcl-2,p-AKT,and p-ERK expression,upregulation of Bax and PARP(all P<0.05),and no significant changes in pan-AKT and pan-ERK expression(all P<0.05).Conclusion Pomegranate can inhibit the growth and proliferative activity of gastric cancer cells by regulating signaling pathways such as PI3K/AKT and MAPK/ERK,thereby exerting therapeutic effects against gastric cancer.
刘泽洋;梁良;潘博宇;吴春暖
天津中医药大学中药学院,天津 301617聊城市人民医院药学部,山东 聊城 252000天津医科大学肿瘤医院肿瘤分子药理研究室,天津 300060天津中医药大学中药学院,天津 301617
石榴网络药理学分子对接技术细胞实验作用机制胃癌
PomegranateNetwork pharmacologyMolecular docking technologyCellular experimentsMechanism of actionGastric cancer
《新医学》 2026 (5)
526-539,14
国家自然科学基金(81703454)
评论